Idorsia launches at-market rights offering targeting gross proceeds of approx. CHF 575m

Niederer Kraft Frey is acting as counsel to Idorsia Ltd in the rights offering that Idorsia launched today. The targeted gross proceeds from the offering of CHF 575 million will be used to support the regulatory filing and, if approved, commercial launch of daridorexant, Idorsia’s dual orexin receptor antagonist, and to fund the clinical development of its other late-stage compounds as well as early-stage pipeline assets.

The NKF team is led by partner Philipp Haas, working with senior associates Deirdre Ní Annracháin and Andrea Giger, associate Shu Bernet-Zhang, and junior associates Sven Pinter and Stephanie Huchler (all Capital Markets).